PT2313087T - Forma de dosagem farmacêutica para libertação imediata de um derivado de indolina - Google Patents

Forma de dosagem farmacêutica para libertação imediata de um derivado de indolina

Info

Publication number
PT2313087T
PT2313087T PT09757601T PT09757601T PT2313087T PT 2313087 T PT2313087 T PT 2313087T PT 09757601 T PT09757601 T PT 09757601T PT 09757601 T PT09757601 T PT 09757601T PT 2313087 T PT2313087 T PT 2313087T
Authority
PT
Portugal
Prior art keywords
dosage form
pharmaceutical dosage
immediate release
indolinone derivative
indolinone
Prior art date
Application number
PT09757601T
Other languages
English (en)
Inventor
Messerschmid Roman
Lach Peter
Sokoliess Torsten
Stopfer Peter
Trommeshauser Dirk
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2313087(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2313087T publication Critical patent/PT2313087T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Educational Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Educational Administration (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT09757601T 2008-06-06 2009-06-04 Forma de dosagem farmacêutica para libertação imediata de um derivado de indolina PT2313087T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157750 2008-06-06

Publications (1)

Publication Number Publication Date
PT2313087T true PT2313087T (pt) 2019-02-15

Family

ID=41017080

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09757601T PT2313087T (pt) 2008-06-06 2009-06-04 Forma de dosagem farmacêutica para libertação imediata de um derivado de indolina

Country Status (35)

Country Link
US (3) US20110190318A1 (pt)
EP (1) EP2313087B2 (pt)
JP (2) JP5583119B2 (pt)
KR (1) KR20110022586A (pt)
CN (1) CN102056599A (pt)
AR (1) AR072060A1 (pt)
AU (1) AU2009254556B2 (pt)
BR (1) BRPI0913235A2 (pt)
CA (1) CA2726648A1 (pt)
CL (1) CL2010001362A1 (pt)
CO (1) CO6280468A2 (pt)
CY (1) CY1121272T1 (pt)
DK (1) DK2313087T4 (pt)
EA (1) EA201001857A1 (pt)
EC (1) ECSP10010717A (pt)
ES (1) ES2711913T5 (pt)
FI (1) FI2313087T4 (pt)
HR (1) HRP20190181T4 (pt)
HU (1) HUE042524T2 (pt)
IL (1) IL209055A0 (pt)
LT (1) LT2313087T (pt)
MA (1) MA32386B1 (pt)
MX (1) MX338001B (pt)
PE (1) PE20100050A1 (pt)
PL (1) PL2313087T5 (pt)
PT (1) PT2313087T (pt)
RS (1) RS58280B2 (pt)
SG (1) SG191607A1 (pt)
SI (1) SI2313087T2 (pt)
TR (1) TR201901579T4 (pt)
TW (1) TW201002692A (pt)
UA (1) UA107560C2 (pt)
UY (1) UY31876A (pt)
WO (1) WO2009147220A1 (pt)
ZA (1) ZA201007972B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
RS57142B1 (sr) * 2008-06-06 2018-07-31 Boehringer Ingelheim Int Farmaceutski dozni oblik u vidu kapsule koji sadrži formulaciju suspenzije indolinon derivata
CA2883807A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP3004224B1 (en) 2013-06-04 2022-01-26 Monosol, LLC Water-soluble film sealing solutions, related methods, and related articles
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
CN111278442B (zh) 2017-10-23 2023-06-06 勃林格殷格翰国际有限公司 用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合
JOP20200212A1 (ar) 2018-03-07 2020-09-01 Pliant Therapeutics Inc مركبات حمض أميني وطرق استخدامها
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
DK1948180T3 (da) * 2005-11-11 2013-05-27 Boehringer Ingelheim Int Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
RS57142B1 (sr) * 2008-06-06 2018-07-31 Boehringer Ingelheim Int Farmaceutski dozni oblik u vidu kapsule koji sadrži formulaciju suspenzije indolinon derivata
NZ588957A (en) * 2008-06-06 2013-03-28 Boehringer Ingelheim Int Pharmaceutical combination of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid
JP2012515184A (ja) * 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010130757A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
PL2313087T3 (pl) 2019-05-31
UA107560C2 (uk) 2015-01-26
ZA201007972B (en) 2011-07-27
AR072060A1 (es) 2010-08-04
EP2313087B2 (en) 2023-11-22
US20140163040A1 (en) 2014-06-12
TW201002692A (en) 2010-01-16
MX2010013092A (es) 2011-02-25
WO2009147220A1 (en) 2009-12-10
ES2711913T3 (es) 2019-05-08
MA32386B1 (fr) 2011-06-01
CY1121272T1 (el) 2020-05-29
PE20100050A1 (es) 2010-01-29
EA201001857A1 (ru) 2011-06-30
SI2313087T1 (sl) 2019-03-29
ES2711913T5 (es) 2024-06-24
AU2009254556B2 (en) 2015-08-20
CN102056599A (zh) 2011-05-11
AU2009254556A1 (en) 2009-12-10
SI2313087T2 (sl) 2024-03-29
HRP20190181T4 (hr) 2024-07-05
JP5583119B2 (ja) 2014-09-03
JP2014098045A (ja) 2014-05-29
US20130203773A1 (en) 2013-08-08
HUE042524T2 (hu) 2019-07-29
TR201901579T4 (tr) 2019-02-21
EP2313087A1 (en) 2011-04-27
MX338001B (es) 2016-03-30
CA2726648A1 (en) 2009-12-10
DK2313087T3 (en) 2019-02-18
IL209055A0 (en) 2011-01-31
US20110190318A1 (en) 2011-08-04
ECSP10010717A (es) 2011-02-28
CL2010001362A1 (es) 2011-05-13
RS58280B1 (sr) 2019-03-29
UY31876A (es) 2010-01-29
PL2313087T5 (pl) 2024-03-04
JP5992937B2 (ja) 2016-09-14
EP2313087B1 (en) 2018-11-21
DK2313087T4 (da) 2024-01-15
HRP20190181T1 (hr) 2019-03-22
BRPI0913235A2 (pt) 2016-01-19
JP2011522010A (ja) 2011-07-28
RS58280B2 (sr) 2024-02-29
FI2313087T4 (fi) 2023-12-28
SG191607A1 (en) 2013-07-31
CO6280468A2 (es) 2011-05-20
LT2313087T (lt) 2019-02-25
KR20110022586A (ko) 2011-03-07

Similar Documents

Publication Publication Date Title
ZA201007972B (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
ZA201102406B (en) Pharmaceutical composition for modified release
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
HK1164059A1 (en) Compositions for drug administration
IL214628A (en) Oral forms for the delayed release of r- Baclofen prodrug
HK1198287A1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1-
EP2493469A4 (en) PHARMACEUTICAL COMPOSITION WITH AN INDOIND CONNECTION
HK1209649A1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives 2--1-
HUE037915T2 (hu) Gyógyszerészeti készítmények aktív vegyületek felszabadítására
GB0802873D0 (en) Pharmaceutical dosage forms for delayed and extended release